• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

Recent Advances in the Study of 2-(Methylsulfanyl)methylaniline (CAS: 34774-84-0) in Chemical Biology and Pharmaceutical Research

The compound 2-(methylsulfanyl)methylaniline (CAS: 34774-84-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug development. The information presented herein is derived from recent peer-reviewed publications, patents, and industry reports, ensuring the accuracy and relevance of the content.

Recent studies have highlighted the versatility of 2-(methylsulfanyl)methylaniline as a key intermediate in the synthesis of various pharmacologically active molecules. Its structural motif, which includes a methylsulfanyl group attached to a methylaniline backbone, has been shown to confer unique reactivity and binding properties. Researchers have exploited these characteristics to develop novel compounds with enhanced biological activity, particularly in the areas of antimicrobial and anticancer therapeutics. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of derivatives of 2-(methylsulfanyl)methylaniline in inhibiting the growth of multidrug-resistant bacterial strains.

In addition to its role as a synthetic intermediate, 2-(methylsulfanyl)methylaniline has been investigated for its direct biological effects. Mechanistic studies have revealed that this compound can modulate specific enzymatic pathways, including those involved in oxidative stress and inflammation. A recent preprint on bioRxiv reported that 2-(methylsulfanyl)methylaniline exhibits potent antioxidant properties, potentially making it a candidate for the treatment of neurodegenerative diseases. These findings underscore the compound's dual utility as both a building block for drug design and a bioactive agent in its own right.

The synthesis and scale-up of 2-(methylsulfanyl)methylaniline have also been areas of active research. Advances in catalytic methods have enabled more efficient and environmentally friendly production of this compound. A 2022 patent application by a leading pharmaceutical company described a novel catalytic system that significantly reduces the use of hazardous reagents while maintaining high yields. Such innovations are critical for ensuring the sustainable production of 2-(methylsulfanyl)methylaniline and its derivatives, particularly as demand for these compounds grows in both academic and industrial settings.

Looking ahead, the potential applications of 2-(methylsulfanyl)methylaniline appear promising but warrant further investigation. Current research is exploring its use in combination therapies, where its unique properties could synergize with existing drugs to enhance efficacy or reduce side effects. Additionally, computational modeling studies are being employed to predict new derivatives with optimized pharmacokinetic profiles. As the body of evidence grows, 2-(methylsulfanyl)methylaniline is poised to become an increasingly important tool in the chemists' arsenal for drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)